Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on October 21, 2025. The filing addresses Item 5.02 regarding the departure of directors/officers and compensatory arrangements. The company is currently engaged in a merger transaction with Decoy Therapeutics, Inc., governed by a Merger Agreement originally entered into on January 10, 2025, and amended multiple times through September 17, 2025.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a specific transaction bonus of $225,000 granted to an executive.
Material Changes
The material change reported is the Board of Directors' approval of a transaction bonus for Mark J. Rosenblum, the Acting Chief Executive Officer, Executive Vice President, and Chief Financial Officer. This bonus is contingent upon the closing of the merger with Decoy Therapeutics and Mr. Rosenblum's continued employment through the Closing Date.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or general management commentary beyond the specific details of the executive compensation. There are no disclosed risks, contingencies, or unusual items other than the pending merger transaction itself.
Investor Verification Checklist
- Verify the status of the Merger Agreement between Salarius Pharmaceuticals and Decoy Therapeutics.
- Confirm the expected Closing Date for the merger to determine the timing of the $225,000 bonus payment.
- Review prior filings to understand the full scope of amendments made to the Merger Agreement between January and September 2025.
- Check for any subsequent filings regarding the finalization of the merger or changes in executive leadership.